Hydroxychloroquine inhalation - APT Pharmaceuticals/Aradigm
Alternative Names: APT-001; APT-002; APT-003; ARD 1300; HCQLatest Information Update: 23 Dec 2021
At a glance
- Originator APT Pharmaceuticals Inc; Aradigm Corporation
- Class Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Quinolines; Small molecules
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Sarcoidosis
Most Recent Events
- 13 Dec 2010 Discontinued - Phase-II for Asthma in Australia (Inhalation)
- 13 Dec 2010 Discontinued - Phase-II for Asthma in USA (Inhalation)
- 10 Apr 2008 Phase II development is ongoing